Skip to main content
Premium Trial:

Request an Annual Quote

Response Biomedical Inks Distribution Deal with Fisher HealthCare

NEW YORK (GenomeWeb News) – Response Biomedical today said that it has signed a new, nonexclusive deal for Fisher HealthCare to distribute its portfolio of infectious disease tests in the US.

Fisher HealthCare, which is part of Thermo Fisher Scientific, will distribute Response Bio's Infectious Disease Point of Care test panel, which includes the Ramp Flu A + B test and the Ramp RSV test. The assays run on the firm's Ramp 200 system.

"This is a key strategic agreement for Response as we continue our investment into the US marketplace for POC testing," Tim Shannon, SVP of worldwide sales and marketing for Response Biomedical, said in a statement. "The knowledge and experience of Fisher HealthCare in this market is a vital part of our strategy to substantially increase our penetration into this highly competitive region."

Earlier this month, Vancouver, British Columbia-based Response Bio signed a US distribution deal with Labsco covering its cardiovascular portfolio of Ramp products.